InnoCan Pharma joined a panel of cannabis movers and shakers from across the globe at Benzinga’s Virtual Cannabis Capital Conference on October 15. Click here for more coverage of this event with presentations from some of the top CEOs, investors and lenders in the cannabis space.
If there was ever a time when the world looked at pharmaceutical companies with capes, and not with horns, it is now.
The pandemic has triggered a global race to find a treatment for COVID-19 with many pharmaceutical companies researching potential vaccines and treatments.
As per studies, although COVID-19 affects different organs in the body, the high mortality rates are mainly caused by the effect of the lungs, causing pneumonia that rapidly progresses to acute respiratory distress syndrome and can further result in respiratory failure and in severe cases, death.
In the cannabis industry, pharma companies are well aware of the therapeutic applications of the plant. But, can its properties be considered apt to fight lung inflammation caused by COVID-19?
InnoCan Pharma certainly thinks so.